A serum-based DNA methylation assay provides accurate detection of glioma.

ABSTRACT:

Background

The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up of cancer patients. However, the significance of cfDNA clinical utility remains uncertain in patients with brain tumors, primarily because of the limited sensitivity cfDNA has to detect real tumor-specific somatic mutations. This unresolved challenge has prevented accurate follow-up of glioma patients with noninvasive approaches.

Methods

Genome-wide DNA methylation profiling of tumor tissue and serum cfDNA of glioma patients.

Results

Here, we developed a noninvasive approach to profile the DNA methylation status in the serum of patients with gliomas and identified a cfDNA-derived methylation signature that is associated w

SUBMITTER: Sabedot TS 

PROVIDER: S-EPMC8408843 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature